Abbott, Abbott Park, Ill, has announced that its Alinity m molecular diagnostics system and assays have received the CE mark. The company’s new technology will help keep up with the growing demand for infectious disease testing. Alinity m will provide flexibility in molecular diagnostic testing, allowing more tests to be performed in shorter timeframes, while reducing the number of instruments and amount of floorspace needed to conduct a large volume of tests.
“To design Alinity m, we spent countless hours with hundreds of lab directors around the world to address the challenges they face, including higher testing volumes; managing complex, labor-intensive processes; and doing so with less time and space,” says John Carrino, divisional vice president for molecular diagnostics research and development at Abbott. “Alinity m will dramatically increase efficiency while delivering accurate results that patients and healthcare professionals can trust to help make decisions about their health and treatment.”
The World Health Organization reports that more than a billion people around the world are living with infectious diseases. Quick and accurate molecular test results are needed to help prevent the spread of such communicable diseases globally. Advanced molecular testing ensures that those living with such health conditions are diagnosed correctly, and that their subsequent response to treatment can be monitored.
“Molecular laboratories are playing an increasingly important role in providing critical test results, and we’re struggling to keep up with demand,” says Martin Obermeier, MD, CEO of Berlin’s Medical Center for Infectious Diseases. “Alinity m will significantly improve the way we operate laboratories by letting staff run any sample at any time, without the need to group samples, allowing us to focus on giving physicians the information they need to make accurate, timely clinical decisions.”
Alinity m may also reduce the lab’s equipment footprint from four to six instruments down to one—decreasing space requirements as well as the hours required to learn and maintain different instruments.
Now available in countries that recognize the CE mark, Alinity m offers an initial menu of assays that include virologic testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus type 1; sexual health-related testing for Chlamydia trachomatis, Mycoplasma genitalium, Neisseria gonorrhoeae, and Trichomonas vaginalis; and high-risk human papilloma virus testing.
Local product availability may vary depending on geographic location. In the United States, Alinity m is under development and is not commercially available for diagnostic use. For further information, visit Abbott.
Featured image: The Alinity m molecular diagnostics system from Abbott.
